Should I Get Tested for Prostate Cancer? A Practical Guide for Men Over 50

Have you ever stared at a lab order for a PSA test and wondered whether the anxiety is even worth it? You are not alone. The short answer to “should I get tested for prostate cancer” is: it depends on your age, family history, and how you feel about treating a slow-growing cancer that might never harm you. The American Cancer Society reports that about 1 in 8 men will be diagnosed with prostate cancer in their lifetime, yet most diagnosed men do not die from it. That gap between diagnosis and mortality is exactly why screening is a personal decision, not a blanket yes. For some men, knowing the prostate cancer treatment cost China offers may actually lower the barrier to getting checked, because early detection with affordable follow-up options changes the risk calculus entirely.

Prostate Cancer Screening: The Short Answer

Most major guidelines recommend a shared decision-making conversation with your doctor starting at age 50 for average-risk men. That conversation should start at 45 for Black men and those with a first-degree relative diagnosed before 65. And at 40 for men with multiple relatives affected. The test itself — a prostate-specific antigen (PSA) blood draw — takes under five minutes and typically costs between $30 and $100 in the United States without insurance. But the real question is not whether you can afford the blood test. It is whether you are prepared to act on an elevated result. Because a high PSA often leads to more tests, and those tests are not always harmless.

Here is the caveat that makes this complicated: PSA can be elevated for reasons that have nothing to do with cancer. Infection, inflammation, recent ejaculation, even riding a bicycle can nudge the number up. That means a positive screening result sometimes triggers a biopsy that finds nothing. And a biopsy is not a casual procedure — it carries a small risk of infection and bleeding. So the decision to test is really a decision about how much uncertainty you can tolerate.

Who Should Get Tested — and Who Should Not

Being explicit about who should skip screening is what makes the rest of this advice credible. Screening is not for everyone.

Men who typically benefit most from PSA screening:

• Aged 50 to 70 with at least a 10-year life expectancy
• Black men starting at 45 — prostate cancer is more aggressive in this group
• Men with a father or brother diagnosed before 65
• Men with BRCA1 or BRCA2 gene mutations
• Men who would pursue treatment if cancer were found

Men who should probably not get screened:

• Men over 75 with significant other health problems
• Men who would decline treatment even if cancer were detected
• Men with a life expectancy under 10 years
• Men who cannot tolerate a biopsy or would not want one

The U.S. Preventive Services Task Force changed its stance in 2018 from blanket discouragement to individualized decision-making for men 55 to 69. That shift matters. It reflects evidence that screening prevents about 1.3 deaths from prostate cancer per 1,000 men screened over 13 years. Modest, but real.

The Options, Compared

If you decide to get tested, you face a fork in the road: where to do it, and what to do with the result. Different health systems approach this differently. The table below compares what a man considering screening might encounter in three contexts.

Which column suits you depends on your insurance, your location, and your appetite for travel. A man in London facing an 8-week wait for a urology consult might reasonably look at the third column and wonder if flying to Shanghai for a faster workup makes sense. A man in Texas with good insurance probably has no reason to leave home. The point is that cost and speed are not fixed — they are variables you can shop.

What a PSA Result Actually Means — and Does Not Mean

Here is the one thing every man considering this test needs to understand: PSA is a smoke detector, not a camera. It tells you something might be burning. It does not show you the fire.

A normal PSA is generally under 4.0 ng/mL, but that number is not a hard cutoff. Roughly 15% of men with a PSA under 4.0 still have prostate cancer. And about 25% of men with a PSA between 4.0 and 10.0 will have cancer found on biopsy. So a “high” PSA does not equal cancer. It equals a reason to look more carefully.

That next look is usually a multiparametric MRI, which has changed the game since about 2015. A negative MRI can avoid biopsy in many men. A suspicious MRI can guide a targeted biopsy that samples the suspicious area rather than taking random cores. This matters because traditional random biopsy misses about 20% of clinically significant cancers. If you are going to get tested, ask whether MRI-first is available where you are being evaluated. It is not universal, but it is becoming the standard in high-volume centers.

Is Prostate Cancer Screening Necessary Over 60? What the Data Says

The question “is prostate cancer screening necessary over 60″ deserves a direct answer. For men aged 60 to 70, the evidence for screening is strongest. The European Randomized Study of Screening for Prostate Cancer followed over 160,000 men and found that screening reduced prostate cancer mortality by about 20% in the 55–69 age group. That is the best data we have. So if you are 62 and otherwise healthy, the answer leans toward yes — get the conversation started. If you are 78 with heart failure and diabetes, the answer leans toward no. Age alone is not the deciding factor. Competing risks are.

And here is a number that surprises many men: autopsy studies show that about 30% of men over 50 have microscopic prostate cancer that never caused symptoms and never would have. That is the “overdiagnosis” problem in a single statistic. Screening finds some cancers that would have been better left alone. But it also finds aggressive cancers early enough to treat. The tension between those two truths is why no guideline says “everyone should screen” or “no one should screen.”

What It Costs: Screening, Biopsy, and Treatment Abroad

Cost is where the decision often gets real. A PSA test is cheap. A biopsy is not. And treatment ranges from a few thousand dollars for active surveillance to tens of thousands for surgery or radiation. If you are uninsured or underinsured, or if your national health system has long waits, the question “how much does prostate biopsy cost abroad” becomes practical, not hypothetical.

In China, a prostate biopsy at a top-tier public hospital through the international department typically runs $800 to $2,500. That includes the urologist’s fee, the procedure, and pathology. An MRI before the biopsy adds $300 to $800. By comparison, the same workup in the United States often totals $3,000 to $6,000 for uninsured patients. The prostate cancer treatment cost China for a radical prostatectomy at a major center generally falls between $12,000 and $25,000, depending on whether robotic surgery is used and which hospital performs it. In the U.S., that same surgery frequently exceeds $40,000 to $70,000 before insurance. Even with insurance, deductibles and coinsurance can leave a patient paying $5,000 to $15,000 out of pocket.

What is included in those Chinese figures varies. The hospital fee usually covers the surgery, anesthesia, standard hospital room, and routine pathology. It does not cover international travel, accommodation, translation, or post-operative rehabilitation. Those add up. A two-week stay for surgery and initial recovery in Shanghai might add $3,000 to $6,000 in travel and lodging costs. Still, the total often lands well below the U.S. price for the procedure alone.

Practical Considerations: Records, Visas, and Follow-Up

If you are considering a prostate cancer checkup in China — whether for cost, speed, or access to high-volume surgeons — the logistics are manageable but not trivial. You will need your medical records translated into English or Chinese, including any prior PSA results, imaging reports, and biopsy pathology if you have had one. Most international departments at Chinese hospitals accept English-language records, but a translated summary speeds things up.

For visa purposes, medical treatment falls under the S2 visa category, not the M visa. The S2 is a short-stay visa for private affairs, including medical treatment, and requires supporting documentation from the hospital confirming your appointment. Family members accompanying you apply for the same S2 category. Processing takes about one to two weeks at most consulates, but you should allow a month. The hospital’s international department typically provides the invitation letter you need. Do not book flights until the visa is approved.

Payment at Chinese public hospitals is generally required upfront. International departments accept major credit cards and sometimes direct bank transfer. Private international hospitals in Shanghai and Beijing often have direct billing arrangements with international insurers, which can simplify things if your policy covers treatment abroad. Check with your insurer before you travel. Many policies exclude elective procedures abroad unless pre-authorized.

Follow-up after returning home is the piece most men forget. A prostatectomy requires PSA checks every 3 to 6 months for the first few years. If your surgeon is in Shanghai and you live in Manchester, you need a local urologist willing to take over monitoring. That is not always easy to arrange. Some men solve this by returning to China for annual follow-up visits, which adds cost. Others find a local urologist who will accept the Chinese hospital’s records and continue care. Sort this out before you book surgery, not after.

How to Book a Prostate Cancer Checkup in China

The phrase “book prostate cancer checkup China medical tourism” captures a real search pattern: men who have decided to get checked and want to do it efficiently. The process is more straightforward than most assume, but it is not like booking a hotel room. You cannot simply walk into a top-tier Chinese public hospital and request a PSA test the same day unless you go through the international department or a private hospital. Public hospital outpatient clinics operate on a same-day registration system — you show up, take a number, and wait. For a foreigner without Chinese language skills, that is a recipe for frustration.

The practical route is to contact the hospital’s international medical department directly, or work with a coordination service that handles the registration, translation, and escort. A written second opinion from a Chinese urologist typically costs $300 to $500 and can be done remotely using your existing records. A video consultation runs $100 to $300 for a standard international department urologist, or $500 to $800 for a top specialist. These remote options let you decide whether traveling is worthwhile before you commit to a flight. Any consultation fee is typically credited toward on-the-ground coordination if you proceed to treatment within 90 days.

For the best prostate cancer hospital Shanghai, several centers stand out. Fudan University Shanghai Cancer Center handles one of the highest volumes of prostate cancer cases in China and is consistently ranked among the top oncology centers nationwide. Zhongshan Hospital, affiliated with Fudan University, is another major center with strong urology and robotic surgery programs. Both operate international departments with English-speaking staff. Beijing has comparable options, including Peking Union Medical College Hospital, which has a long history of treating international patients. The right choice depends on your specific case, not on a generic ranking.

You can browse our list of top-ranked hospitals across 37 cities to see which centers are recognized for urology and oncology. Or check the specialty rankings for urology and oncology to compare hospitals by department.

Frequently Asked Questions